Our results showed that the baseline EBV DNA load corresponded with clinical response and EBV assessment could predict clinical effects prior to radiographic evaluation and identify RM-NPC patients who could obtain long-term clinical benefit from anti-PD-1 monotherapy. The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.